|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NEMF |
Gene summary for NEMF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NEMF | Gene ID | 9147 |
| Gene name | nuclear export mediator factor | |
| Gene Alias | IDDSAPN | |
| Cytomap | 14q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | O60524 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9147 | NEMF | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.74e-14 | -5.81e-01 | 0.0155 |
| 9147 | NEMF | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.69e-04 | -5.15e-01 | -0.1207 |
| 9147 | NEMF | HTA11_696_2000001011 | Human | Colorectum | AD | 1.17e-02 | -3.11e-01 | -0.1464 |
| 9147 | NEMF | HTA11_866_3004761011 | Human | Colorectum | AD | 7.03e-04 | -3.83e-01 | 0.096 |
| 9147 | NEMF | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.95e-03 | -6.18e-01 | 0.0528 |
| 9147 | NEMF | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.45e-06 | -4.14e-01 | 0.0674 |
| 9147 | NEMF | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.00e-16 | -5.43e-01 | 0.294 |
| 9147 | NEMF | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.67e-07 | -4.21e-01 | 0.3859 |
| 9147 | NEMF | HTA11_99999973899_84307 | Human | Colorectum | MSS | 6.74e-06 | -6.52e-01 | 0.2585 |
| 9147 | NEMF | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.24e-06 | -4.38e-01 | 0.3005 |
| 9147 | NEMF | F007 | Human | Colorectum | FAP | 7.19e-03 | -4.27e-02 | 0.1176 |
| 9147 | NEMF | A001-C-207 | Human | Colorectum | FAP | 2.11e-04 | -8.76e-02 | 0.1278 |
| 9147 | NEMF | A015-C-203 | Human | Colorectum | FAP | 5.73e-31 | -2.19e-01 | -0.1294 |
| 9147 | NEMF | A015-C-204 | Human | Colorectum | FAP | 8.62e-10 | -2.88e-01 | -0.0228 |
| 9147 | NEMF | A014-C-040 | Human | Colorectum | FAP | 7.95e-06 | -6.51e-02 | -0.1184 |
| 9147 | NEMF | A002-C-201 | Human | Colorectum | FAP | 4.61e-17 | -1.63e-01 | 0.0324 |
| 9147 | NEMF | A002-C-203 | Human | Colorectum | FAP | 1.13e-06 | -1.48e-01 | 0.2786 |
| 9147 | NEMF | A001-C-119 | Human | Colorectum | FAP | 8.11e-09 | 6.68e-02 | -0.1557 |
| 9147 | NEMF | A001-C-108 | Human | Colorectum | FAP | 8.83e-19 | 4.06e-02 | -0.0272 |
| 9147 | NEMF | A002-C-205 | Human | Colorectum | FAP | 7.66e-29 | -5.02e-02 | -0.1236 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498 | Colorectum | AD | proteasomal protein catabolic process | 174/3918 | 490/18723 | 3.18e-14 | 7.66e-12 | 174 |
| GO:0043161 | Colorectum | AD | proteasome-mediated ubiquitin-dependent protein catabolic process | 141/3918 | 412/18723 | 1.77e-10 | 1.68e-08 | 141 |
| GO:0006913 | Colorectum | AD | nucleocytoplasmic transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0051169 | Colorectum | AD | nuclear transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
| GO:0051168 | Colorectum | AD | nuclear export | 53/3918 | 154/18723 | 6.89e-05 | 1.11e-03 | 53 |
| GO:0006414 | Colorectum | AD | translational elongation | 21/3918 | 55/18723 | 2.53e-03 | 1.93e-02 | 21 |
| GO:00104981 | Colorectum | SER | proteasomal protein catabolic process | 132/2897 | 490/18723 | 3.08e-11 | 5.55e-09 | 132 |
| GO:00431611 | Colorectum | SER | proteasome-mediated ubiquitin-dependent protein catabolic process | 105/2897 | 412/18723 | 7.48e-08 | 4.70e-06 | 105 |
| GO:00069131 | Colorectum | SER | nucleocytoplasmic transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
| GO:00511691 | Colorectum | SER | nuclear transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
| GO:00511681 | Colorectum | SER | nuclear export | 42/2897 | 154/18723 | 1.19e-04 | 2.46e-03 | 42 |
| GO:00064171 | Colorectum | SER | regulation of translation | 100/2897 | 468/18723 | 3.76e-04 | 5.74e-03 | 100 |
| GO:00064141 | Colorectum | SER | translational elongation | 17/2897 | 55/18723 | 3.00e-03 | 2.65e-02 | 17 |
| GO:00104982 | Colorectum | MSS | proteasomal protein catabolic process | 157/3467 | 490/18723 | 2.39e-13 | 5.25e-11 | 157 |
| GO:00431612 | Colorectum | MSS | proteasome-mediated ubiquitin-dependent protein catabolic process | 127/3467 | 412/18723 | 7.70e-10 | 6.32e-08 | 127 |
| GO:00069132 | Colorectum | MSS | nucleocytoplasmic transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
| GO:00511692 | Colorectum | MSS | nuclear transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
| GO:00064172 | Colorectum | MSS | regulation of translation | 134/3467 | 468/18723 | 4.43e-08 | 2.38e-06 | 134 |
| GO:00511682 | Colorectum | MSS | nuclear export | 51/3467 | 154/18723 | 1.01e-05 | 2.43e-04 | 51 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NEMF | SNV | Missense_Mutation | novel | c.934N>T | p.Ala312Ser | p.A312S | O60524 | protein_coding | tolerated(0.09) | benign(0.259) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NEMF | SNV | Missense_Mutation | c.788C>T | p.Pro263Leu | p.P263L | O60524 | protein_coding | deleterious(0.03) | benign(0.124) | TCGA-AR-A1AV-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| NEMF | SNV | Missense_Mutation | c.2301N>T | p.Met767Ile | p.M767I | O60524 | protein_coding | tolerated(0.19) | benign(0) | TCGA-B6-A0X5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| NEMF | SNV | Missense_Mutation | c.1624N>G | p.Ile542Val | p.I542V | O60524 | protein_coding | deleterious(0.03) | benign(0.073) | TCGA-BH-A1F6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| NEMF | SNV | Missense_Mutation | rs370320203 | c.1828N>G | p.Thr610Ala | p.T610A | O60524 | protein_coding | tolerated(0.13) | possibly_damaging(0.669) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NEMF | SNV | Missense_Mutation | rs760379976 | c.1634N>A | p.Arg545Gln | p.R545Q | O60524 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NEMF | SNV | Missense_Mutation | rs764224132 | c.1763G>A | p.Arg588Gln | p.R588Q | O60524 | protein_coding | deleterious(0.01) | probably_damaging(0.957) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| NEMF | SNV | Missense_Mutation | novel | c.2762N>A | p.Pro921His | p.P921H | O60524 | protein_coding | tolerated(0.08) | benign(0.031) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NEMF | SNV | Missense_Mutation | c.2021N>A | p.Arg674Lys | p.R674K | O60524 | protein_coding | tolerated(0.84) | benign(0) | TCGA-EA-A78R-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NEMF | SNV | Missense_Mutation | c.2781G>C | p.Gln927His | p.Q927H | O60524 | protein_coding | deleterious(0.02) | benign(0.365) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |